Good Distribution Practice (GDP)

A comprehensive, documented Quality Management System (QMS) is the backbone of GDP. It must define organizational structure, procedures, processes, and resources to ensure every product remains within authorized specifications. Key elements include:

• Change Control: A formal process for evaluating and approving any modification to facilities, equipment, or procedures.
• Deviation Management: Systematic logging, investigation, and root cause analysis of any departure from approved procedures.
• CAPA: Corrective and Preventive Actions derived from deviation investigations to prevent recurrence.
• Risk Management: Application of quality risk management principles to all distribution activities, prioritizing controls based on potential patient impact.

GDP mandates that all personnel involved in distribution activities are competent and qualified for their roles. This requires:

• Defined Responsibilities: A clear organizational chart with a designated Responsible Person (RP) who holds legal accountability for GDP compliance.
• Continuous Training: Documented initial and ongoing training programs covering GDP principles, SOPs, and cold chain handling specific to the employee's duties.
• Hygiene Programs: Strict personal hygiene protocols to prevent product contamination, particularly critical for sterile or aseptic products.
• Training effectiveness must be periodically assessed and records retained for regulatory inspection.

All storage facilities and vehicles must be designed, qualified, and maintained to protect medicinal products from environmental degradation and contamination. Critical requirements include:

• Temperature Mapping: Initial and periodic thermal mapping studies of all storage areas and transport lanes to identify hot and cold spots.
• Qualified Equipment: Use of calibrated, maintained, and qualified temperature-controlled vehicles, cold rooms, freezers, and active packaging systems.
• Segregated Storage: Physically separated, access-controlled areas for quarantined, released, rejected, and returned products to prevent mix-ups.
• Alarm Systems: Automated alerting mechanisms with defined escalation paths for equipment failures or temperature excursions.

A robust documentation system provides the audit trail proving that every product was handled correctly at every stage. GDP requires:

• Standard Operating Procedures (SOPs): Detailed, version-controlled instructions for all critical operations, from receiving to dispatch.
• Batch Traceability: Records enabling forward tracking to the customer and backward tracing to the manufacturer for every single batch.
• Data Integrity: Compliance with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) for all electronic and paper records.
• Record Retention: Archiving of all distribution records for a period defined by national legislation, typically at least five years after batch expiry.

Transportation must be conducted under validated conditions that maintain product integrity throughout the journey. This pillar encompasses:

• Lane Qualification: Documented evidence that the chosen transport route and mode can consistently maintain the required temperature range under worst-case seasonal conditions.
• Active & Passive Systems: Selection and qualification of active refrigeration units or passive packaging (e.g., Phase Change Materials) based on duration and ambient profile.
• Real-Time Monitoring: Deployment of calibrated IoT sensor telemetry with configurable logging intervals to capture temperature, humidity, and shock data during transit.
• Excursion Management: Pre-defined procedures for the immediate assessment and disposition of products exposed to a cold chain break, including segregation and quarantine pending a quality impact evaluation.

GDP establishes strict protocols for handling product returns and preventing the infiltration of falsified medicines into the legitimate supply chain. Requirements include:

• Returns Authorization: A formal, risk-based process for assessing returned products before they are allowed back into saleable stock, with special scrutiny for cold chain products where integrity may be compromised.
• Complaint Handling: A system for logging, investigating, and trending all quality complaints, with mandatory reporting of confirmed product defects to the manufacturer and competent authorities.
• Serialization Verification: Compliance with regulations like the EU Falsified Medicines Directive (FMD) , requiring verification of unique identifiers and anti-tampering devices at the point of dispensing.
• Segregation of Suspect Product: Immediate quarantine of any product suspected of being counterfeit, contaminated, or otherwise non-compliant.

The operational manifestation of GDP principles for temperature-sensitive medicinal products. Compliance requires a documented, continuous chain of temperature control, monitoring, and custody transfer from manufacturer to patient. Key elements include:

• Validated storage and transport equipment
• Calibrated monitoring devices with audit trails
• Defined roles for the Responsible Person (RP)
• Deviation management and CAPA procedures

A core GDP requirement mandating a systematic response to any temperature deviation outside the product's labeled storage conditions. The process includes:

• Immediate detection via real-time monitoring
• Segregation and quarantine of affected stock
• Impact assessment using stability data and Mean Kinetic Temperature (MKT) calculations
• Documented disposition decision by a Qualified Person (QP)
• Root cause analysis to prevent recurrence

The serialized identification system that enables forward tracking and backward tracing of each medicinal product unit throughout the distribution network. Under GDP, this ensures:

• Verification of product authenticity at each custody transfer
• Rapid, targeted recall execution when quality is compromised
• Compliance with regulations such as the EU Falsified Medicines Directive (FMD) and US Drug Supply Chain Security Act (DSCSA)

The FDA regulation defining criteria for electronic records and electronic signatures to be considered trustworthy and equivalent to paper records. For GDP-compliant monitoring systems, this mandates:

• Secure, computer-generated, time-stamped audit trails
• Authority checks to ensure only authorized individuals access the system
• Device checks to validate data integrity at the point of capture
• Archival of records for the required retention period

A mandatory GDP validation study that places calibrated data loggers throughout a storage area or transport lane to identify temperature distribution patterns. The study must be conducted under worst-case conditions (summer and winter) and repeated at defined intervals. Outputs include:

• Identification of hot spots and cold spots
• Determination of monitoring probe placement
• Definition of safe loading patterns and storage configurations

The individual designated under GDP regulations with legal accountability for ensuring the quality management system is implemented and maintained. The RP must:

• Be continuously contactable and reside in the relevant jurisdiction
• Approve all subcontractors and customers
• Ensure self-inspections are conducted at regular intervals
• Decide on the final disposition of returned or recalled products
• Maintain a documented training program for all staff